Specialty Pharmacy

Understanding the complicated web of insurers, discounts from government and commercial plans, and payer access is extremely complicated.

Managing understaffing and increasingly demanding workflows is an ongoing challenge in pharmacy.

A specialty pharmacy can effectively dispense, monitor, and follow-up with transplant patients who are maintained on the standard triple-drug immunosuppression regimen.

New data identifying a particular gene expression signature will be presented at the 2023 ASCO Genitourinary Symposium.

The drive for personalized approaches to cancer have helped to create treatments for patients with rare cancers who have few, if any, options.

Study shows no robust differences in blood pressure, heart rate, lipids, and glucose measurements in children conceived using assisted reproductive technologies.

Expanded indication for abrocitinib (Cibinqo; Pfizer Inc) includes patients 12 to <18 years of age with refractory, moderate-to-severe atopic dermatitis that is not adequately controlled with other systemic medications.

By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in reduced bone loss.

Paroxysmal nocturnal hemoglobinuria is a rare and life-threatening blood condition.

Although specialty pharmacy has mirrored health care IT’s explosive growth and market innovation over the past several decades, the industry has not advanced significantly in dispensing software.

Belimumab was the first and only approved biologic for active systemic lupus erythematosus and lupus nephritis in more than 50 years, including for pediatric patients.

Specialty medication has grown to about 55% of net spending, which is up by 28% since 2011 mostly driven by autoimmune diseases and oncology.

Availability of TNF-alpha inhibitor biosimilars in Southern European markets led to lowered costs within the drug class, even after an increased consumption volume for these therapies.

The need for pharmacists to return to a more clinically-focused role became apparent as the COVID-19 pandemic revealed gaps in patient access to care across the country.

In the United States, 91% of states had lower rates of targeted therapy use than expected.

Amjevita is approved for all indications of reference Humira except for hidradenitis suppurativa.

Patients who received first-line ICI showed a significant improvement in progression-free survival (PFS) and overall survival (OS) compared to chemotherapy treatment.

At leukapheresis, a low frequency of differentiated CD3+CD27-CD28--T cells can indicate favorable response to CAR T-cell therapy.

Zolbetuximab treatment reduced risk of death by 25% compared to placebo.

During the COVID-19 pandemic, patients were able to utilize telehealth services to receive care more conveniently, which may reduce the cost of care.

NRTIs TAF and TDF are increasingly being used as preexposure prophylaxis (PrEP) to prevent HIV around the world.

OR-449 is being developed for both adult and pediatric patients with adrenocortical carcinoma, as well as other cancers known to express a high level of steroidogenic factor-1.

Sarah McDonald, cancer survivor and author of The Cancer Channel, discusses her experience battling 2 different unrelated cancers and the value oncology pharmacists could have provided with a greater presence on her care team.

Inequities were also apparent between those who saw and did not see neurologists, analysis shows.

Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 inhibitor that inhibits cytokine signaling in psoriasis pathogenesis.

The stool-test is the first-of-its-kind to detect CRC in adults aged 45 to 49 years, with a premarket approval submission planned to be sent to the FDA early in 2023.

Research shows that some unsuccessful switches from reference products to biosimilars may be attributed to patient perceptions of reduced efficacy and safety.

The head of the CAR T cell antibody can recognize and target the growth factor in its tumor microenvironment.

YLB113 (Nepexto) produced significantly lower injection site reactions and injection site erythema compared with etanercept in patients with rheumatoid arthritis.

The analysis found a median progression-free survival of 14.2 months in the ripretinib arm, compared with 1.5 months in the sunitinib arm.